Literature DB >> 34093893

The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Masha Maharaj1, Lucille Heslop2, Trisha Govender1, Nisaar Korowlay3, Aviral Singh4, Partha Choudhary5, Mike Sathekge6.   

Abstract

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge 177Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m2 weekly × 6 weeks) as a radiosensitizer with re-challenge 177Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of 177Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge 177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  177Lu; Docetaxel; PSMA; Prostate cancer; Radiosensitizer; Re-challenge

Year:  2021        PMID： 34093893      PMCID： PMC8139998          DOI： 10.1007/s13139-021-00696-5

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  15 in total

1.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.

Authors:  Jaspreet S Batra; Muhammad Junaid Niaz; Young E Whang; Arif Sheikh; Charlene Thomas; Paul Christos; Shankar Vallabhajosula; Yuliya S Jhanwar; Ana M Molina; David M Nanus; Joseph R Osborne; Neil H Bander; Scott T Tagawa
Journal:  Urol Oncol       Date:  2020-06-27       Impact factor: 3.498

2.  Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Authors:  Andrei Gafita; Hui Wang; Robert Tauber; Calogero D'Alessandria; Wolfgang A Weber; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

3.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Authors:  Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-22       Impact factor: 9.236

Review 4.  PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Markus Essler; Hans Jürgen Biersack
Journal:  Semin Nucl Med       Date:  2019-08-21       Impact factor: 4.446

5.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Authors:  Anna Yordanova; Paula Linden; Stefan Hauser; Michael Meisenheimer; Stefan Kürpig; Georg Feldmann; Florian C Gaertner; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-24       Impact factor: 9.236

6.  Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).

Authors:  Parul Thakral; Ishita Sen; Vineet Pant; Santosh Kumar Gupta; Sugandha Dureja; Jyotsna Kumari; Sunil Kumar; Pallavi Un; Vindhya Malasani
Journal:  Br J Radiol       Date:  2018-07-27       Impact factor: 3.039

7.  Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action.

Authors:  Amanda L Dunne; Carmel Mothersill; Tracy Robson; George D Wilson; David G Hirst
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

8.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

9.  Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.

Authors:  Andrei Gafita; Isabel Rauscher; Margitta Retz; Karina Knorr; Matthias Heck; Hans-Jürgen Wester; Calogero D'Alessandria; Wolfgang A Weber; Matthias Eiber; Robert Tauber
Journal:  J Nucl Med       Date:  2018-11-15       Impact factor: 10.057

10.  Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Authors:  Marcus P Kelly; Sze Ting Lee; F-T Lee; Fiona E Smyth; Ian D Davis; Martin W Brechbiel; Andrew M Scott
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.